Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The most common side effects are nausea, diarrhea, constipation, vomiting, and temporary changes in appetite
Originally developed to help regulate blood sugar for individuals with type 2 diabetes, these medications have gained recognition for their ability to support weight loss and appetite control
Incretin-based multi-agonists, such as tirzepatide and retatrutide, target two or more receptors among GLP-1, GIP, and GCGR to enhance insulin secretion, improve fat metabolism, and increase energy expenditureultimately achieving greater weight loss and metabolic improvement
Information provided by Blue Cross and Blue Shield of Texas is for informational and educational purposes only and is not a substitute for the independent medical judgment of a physician or other health care provider, nor is the information presented intended to replace or supersede any requirements set forth in your contract with BCBSTX
Risks The GLP-1 agonists operate by inducing a sensation of fullness and delaying gastric emptying
US$ 27.95
US$ 22.18
US$ 22.25
US$ 25.86
